<div id="readability-page-1"><p><strong>CVS Health Co.</strong> (NYSE:CVS - Get Free Report) announced a quarterly dividend on Thursday, March 20th, RTT News reports. Investors of record on Tuesday, April 22nd will be given a dividend of 0.665 per share by the pharmacy operator on Thursday, May 1st. This represents a $2.66 dividend on an annualized basis and a yield of 3.89%.</p><ul><li>Walgreens Boots Alliance: Don’t Write Off This Asset Champ Yet</li></ul><p>CVS Health has raised its dividend by an average of 10.0% per year over the last three years. CVS Health has a payout ratio of 38.8% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect CVS Health to earn $6.77 per share next year, which means the company should continue to be able to cover its $2.66 annual dividend with an expected future payout ratio of 39.3%. </p><h2>CVS Health Stock Up 0.8 %</h2><p>Shares of CVS stock traded up $0.55 on Thursday, hitting $68.46. 2,210,006 shares of the stock were exchanged, compared to its average volume of 11,031,100. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80. The firm has a market capitalization of $86.32 billion, a P/E ratio of 18.71, a price-to-earnings-growth ratio of 0.98 and a beta of 0.54. The business has a 50-day moving average of $59.76 and a 200 day moving average of $57.20. CVS Health has a fifty-two week low of $43.56 and a fifty-two week high of $80.75. </p><ul><li>3 Beaten Down Healthcare Stocks Recovering in 2025</li></ul><p>CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%.  Equities analysts anticipate that  CVS Health will post 5.89 EPS for the current year. </p><h2>Wall Street Analyst Weigh In</h2><p>CVS has been the subject of a number of recent analyst reports. TD Cowen raised their price objective on CVS Health from $73.00 to $80.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, November 25th. Deutsche Bank Aktiengesellschaft raised CVS Health from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $66.00 price objective for the company in a research report on Tuesday, December 3rd. Argus  set a $77.00 price objective on CVS Health in a research report on Tuesday, February 18th. Wells Fargo &amp; Company increased their target price on CVS Health from $68.00 to $73.00 and gave the stock an &#34;overweight&#34; rating in a research note on Thursday, February 13th. Finally, Cantor Fitzgerald upgraded CVS Health from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating in a research note on Wednesday, February 12th. Four research analysts have rated the stock with a hold rating, seventeen have assigned  a buy rating and one  has assigned  a strong buy rating to the company's stock. According to data from MarketBeat.com, the company  has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $69.83.</p><ul><li>Humana Gains Despite Medicare Advantage Losses—What’s the Catch?</li></ul><p><b>Get Our Latest Stock Analysis on CVS</b></p><h2>Insider Transactions at CVS Health</h2><p>In other news, Director Michael F. Mahoney bought 30,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was acquired at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the transaction, the director now directly owns 39,356 shares of the company's stock, valued at approximately $2,625,045.20. This represents a 320.65 % increase in their position. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, SVP James David Clark sold 7,513 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now directly owns 8,394 shares of the company's stock, valued at $556,941.90. The trade was a 47.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own  0.24% of the company's stock. </p><h2>CVS Health Company Profile</h2> (Get Free Report)<p>CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy &amp; Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.</p><h2>See Also</h2><ul><li>Five stocks we like better than CVS Health</li><li>Where to Find Earnings Call Transcripts</li><li>Everything About Amazon Stock Signals a Buy—Time to Load Up?</li><li>What is a Dividend Harvesting Strategy and How Can Investors Profit from it?</li><li>5 Reasons Five Below’s Stock Price Is Heading Higher This Year</li><li>What is a Dividend King? </li><li>Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/DividendChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/DividendChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in CVS Health Right Now?</h2><p>Before you consider CVS Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.</p><p>While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>CVS Health Co. (NYSE:CVS) has declared a quarterly dividend of $0.67, payable on May 1st to shareholders of record on April 22nd. This annualizes to $2.66, yielding 3.89%. The company has increased its dividend by an average of 10% annually over the past three years, with a payout ratio of 38.8%. CVS stock rose 0.8% to $68.46, with analysts projecting earnings of $6.77 per share next year. Recent analyst ratings show a consensus of "Moderate Buy" with an average price target of $69.83.</p>

CVS Health Co. (NYSE:CVS) Declares Quarterly Dividend of $0.67